Skip to main content

Table 1 Demographics of patients

From: Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

  Demography
SCLC LCNEC
Number/Median %/Range Number/Median %/Range
Total patients 72,381   3496  
Sex
 Male 36,406 50.30% 1928 55.15%
 Female 35,975 49.70% 1568 44.85%
Race
 White 63,192 87.30% 2919 83.50%
 Black 6284 8.68% 423 12.10%
 Other/unknown 2905 4.01% 154 4.41%
Total patients with SPM 1022 1.41% 139 3.98%
Sex
 Male 458 44.81% 68 48.92%
 Female 564 55.19% 71 51.08%
Race
 White 899 87.96% 113 81.29%
 Black 85 8.32% 19 13.67%
 Other/unknown 38 3.72% 7 5.04%
Patients with 1 SPM 862 1.20% 117 3.35%
Sex
 Male 384 44.55% 57 48.72%
 Female 478 55.45% 60 51.28%
Race
 White 755 87.59% 96 82.05%
 Black 74 8.58% 15 12.82%
 Other/unknown 33 3.83% 6 5.13%
Patients with 2 or more SPM 160 0.23% 22 0.63%
Sex
 Male 74 46.25% 11 50%
 Female 86 53.75% 11 50%
Race
 White 143 89.38% 17 77.27%
 Black 12 7.50% 4 18.18%
 Other/unknown 5 3.12% 1 4.55%
Age for SPM (median) 64 years (36-88 years) 66 years (37-82 years)
Latency (median) 3.58 years (0.5–16.42 years) 3.33 years (0.67-15 years)
Follow-up (median) 5.42 years (0.5–16.92 years) 5.92 years (0.67–15.75 years)